Tralopyril
Based on 1 Customer Validation
Tralopyril is an orally active, blood-brain barrier-penetrating antifouling insecticide and endocrine disruptor. By interfering with the thyroid hormone system and mitochondrial oxidative phosphorylation, Tralopyril downregulates the transcription of genes such as TRHR, Nkx2.1, TRα and induces ferroptosis. Tralopyril disrupts amino acid, energy and lipid metabolism, exhibits significant skeletal and reproductive toxicity, and causes developmental damage. Tralopyril has a long half-life in vivo and wide tissue distribution, posing potential risks to aquatic organisms and human health. Tralopyril shows species specificity in in vitro liver microsomal metabolism, exerts lethal effects on target insects and laboratory animals, and is commonly used in studies of chlorfenapyr poisoning and related toxic mechanisms.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 122454-29-9
- Formula: C12H5BrClF3N2
- Molecular Weight:349.53
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Tralopyril potently inhibits growth, ATP production, and effective quantum yield in Chlamydomonas reinhardtii cells[1].
Tralopyril (200 μM; 0, 5, 15, 30, 45, 60 min) exhibits low metabolic clearance in human and monkey liver microsomes, moderate clearance in mouse, rat, and dog liver microsomes, with interspecies differences in in vitro metabolic stability[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tralopyril (45 mg/kg; p.o.), the in vivo metabolite of chlorfenapyr, has a significantly longer half-life (5.39 h), higher AUC0-t, and higher Cmax than chlorfenapyr, and it distributes widely across all mouse tissues including the brain[3].
Tralopyril (27 mg/kg; p.o.; single dose) has an oral LD50 of 27 mg/kg in male rats, indicating acute lethal toxicity via this route[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 8-9 weeks old, 22-25 g, SPF-grade)[3]
-
Dosage:45 mg/kg (generated in vivo via metabolic conversion of chlorfenapyr)
-
Administration:p.o.
-
Result:Exhibited a half-life of 5.39 h, area under the curve (AUC(0-t)) of 15912.77 μg/L*h, peak concentration (Cmax) of 4212.48 μg/L, and time to peak concentration (Tmax) of 0.42 h.
Was widely distributed across all tested tissues (heart, liver, spleen, lung, kidney, brain, skeletal muscle, stomach, intestine, plasma), including crossing the blood-brain barrier.
Was cleared more slowly than chlorfenapyr, with detectable levels in most tissues for up to 24 hours post-administration.
Chemical Information
-
CAS No. 122454-29-9
-
Appearance Solid
-
Molecular Weight 349.53
-
Formula C12H5BrClF3N2
-
Color White to off-white
-
SMILES
C1=C(C=CC(=C1)Cl)C2=C(C#N)C(=C(C(F)(F)F)N2)Br
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 8.75 mg/mL (25.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen X, et al. Tralopyril induces developmental toxicity in zebrafish embryo (Danio rerio) by disrupting the thyroid system and metabolism. Sci Total Environ. 2020;746:141860. [Content Brief]
[3]. Zhang S, et al. Toxicokinetics, in vivo metabolic profiling and tissue distribution of chlorfenapyr in mice. Arch Toxicol. 2024;98(11):3763-3775. [Content Brief]
[4]. Chung MJ, et al. A Fatal Case of Chlorfenapyr Poisoning and the Therapeutic Implications of Serum Chlorfenapyr and Tralopyril Levels. Medicina (Kaunas). 2022;58(11):1630. Published 2022 Nov 11. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8610 mL | 14.3049 mL | 28.6098 mL | 71.5246 mL |
| 5 mM | 0.5722 mL | 2.8610 mL | 5.7220 mL | 14.3049 mL | |
| 10 mM | 0.2861 mL | 1.4305 mL | 2.8610 mL | 7.1525 mL | |
| 15 mM | 0.1907 mL | 0.9537 mL | 1.9073 mL | 4.7683 mL | |
| 20 mM | 0.1430 mL | 0.7152 mL | 1.4305 mL | 3.5762 mL | |
| 25 mM | 0.1144 mL | 0.5722 mL | 1.1444 mL | 2.8610 mL |